Advertisement
Diseases
Subscribe to Diseases
View Sample

FREE Email Newsletter

Ethical issue: Who gets experimental Ebola drug?

August 6, 2014 5:25 pm | by Lauran Neergaard - AP Medical Writer - Associated Press | News | Comments

The use of an experimental drug to treat two Americans diagnosed with Ebola is raising ethical questions about who gets first access to unproven new therapies for the deadly disease. But some health experts fear debate over extremely limited doses will distract from tried-and-true measures to curb the growing outbreak.

Cytori halts stem cell study due to adverse events

August 5, 2014 5:23 pm | by Matthew Perrone - AP Health Writer - Associated Press | News | Comments

Cytori Therapeutics said Tuesday it has halted trials of its experimental stem cell therapy for heart failure after three patients developed blood flow problems. The San Diego-based company said it placed the hold on two studies after the patients developed problems with blood flow to the brain. Two of the patients' symptoms resolved in a short period of time and a third was still recovering, the company said in a statement.

Model of viral lifecycle could help find cure for hepatitis B

August 5, 2014 4:36 pm | by Helen Knight, MIT News correspondent | News | Comments

A new technique for studying the lifecycle of the hepatitis B virus could help researchers develop a cure for the disease. A recently published paper describes using microfabricated cell cultures to sustain hepatitis B virus in human liver cells, allowing them to study immune responses and drug treatments.

Advertisement

NYC hospital testing patient for possible Ebola

August 4, 2014 6:22 pm | by Frank Eltman - Associated Press - Associated Press | News | Comments

A man who recently visited West Africa was placed in isolation at a city hospital and was undergoing tests for possible Ebola, officials said Monday. The man, suffering from a high fever and gastrointestinal symptoms, arrived at Mount Sinai Medical Center in Manhattan early on Monday, the hospital said. He had recently traveled to a West African country where Ebola has been reported, it said.

Researchers uncover clues to flu’s mechanisms

August 4, 2014 3:13 pm | by Mike Williams, Rice Univ. | News | Comments

A flu virus acts like a Trojan horse as it attacks and infects host cells. Scientists at Rice Univ. and Baylor College of Medicine have acquired a clearer view of the well-hidden mechanism involved. Their computer simulations may lead to new strategies to stop influenza, perhaps even a one-size-fits-all vaccine.

U.S. aid workers headed to Atlanta for Ebola care

August 2, 2014 4:21 am | by Mike Stobbe - AP Medical Writer - Associated Press | News | Comments

When two U.S. aid workers infected with Ebola arrive in Atlanta from Africa, they will be whisked into one of the most sophisticated hospital isolation units in the country. The specialized unit at Emory Univ. Hospital was opened a dozen years ago to care for federal health workers exposed to some of the world's most dangerous germs.

Glucose “control switch” in the brain key to both diabetes types

July 31, 2014 9:36 am | by Karen N. Peart, Yale Univ. | News | Comments

Researchers at Yale School of Medicine have pinpointed a mechanism in part of the brain that is key to sensing glucose levels in the blood, linking it to both type 1 and type 2 diabetes. The findings are published in the Proceedings of the National Academies of Sciences.

Researchers find protein that fuels repair of treatment-resistant cancer cells

July 31, 2014 8:06 am | by Laura Bailey, Univ. of Michigan | News | Comments

Imagine you're fighting for your life but no matter how hard you hit, your opponent won't go down. The same can be said of highly treatment-resistant cancers, such as head and neck cancer, where during radiation and chemotherapy some cancer cells repair themselves, survive and thrive. Head and neck cancer is the sixth most common cancer in the world, but the late detection and treatment resistance result in a high mortality rate.

Advertisement

Dissolvable fabric loaded with medicine might offer protection against HIV

July 30, 2014 1:54 pm | by Michelle Ma, Univ. of Washington | News | Comments

Soon, protection from HIV infection could be as simple as inserting a medicated, disappearing fabric minutes before having sex. Univ. of Washington bioengineers have discovered a potentially faster way to deliver a topical drug that protects women from contracting HIV. Their method spins the drug into silk-like fibers that quickly dissolve when in contact with moisture, releasing high doses of the drug.

New brain-based marker of stress susceptibility

July 29, 2014 1:05 pm | by Karl Bates, Duke Univ. | News | Comments

Some people can handle stressful situations better than others, and it’s not all in their genes: Even identical twins show differences in how they respond. Researchers have identified a specific electrical pattern in the brains of genetically identical mice that predicts how well individual animals will fare in stressful situations. The findings may eventually help researchers prevent potential consequences of chronic stress.

Stem cell advance may increase efficiency of tissue regeneration

July 29, 2014 8:52 am | by Jeffrey Norris, UCSF | News | Comments

A new stem cell discovery might one day lead to a more streamlined process for obtaining stem cells, which in turn could be used in the development of replacement tissue for failing body parts, according to Univ. of California, San Francisco scientists who reported the findings in Cell.

Forced mutations doom HIV

July 29, 2014 8:16 am | by Anne Trafton, MIT News Office | News | Comments

Fifteen years ago, Massachusetts Institute of Technology professor John Essigmann and colleagues from the Univ. of Washington had a novel idea for an HIV drug. They thought if they could induce the virus to mutate uncontrollably, they could force it to weaken and eventually die out—a strategy that our immune system uses against many viruses.

$1,000 pill now hepatitis C treatment of choice

July 29, 2014 3:19 am | by Ricardo Alonso-zaldivar - Associated Press - Associated Press | News | Comments

A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than three million Americans. In less than six months, prescriptions for Sovaldi have eclipsed all other hepatitis C pills combined, according to new data from IMS Health.

Advertisement

New protein structure could help treat Alzheimer’s

July 28, 2014 2:16 pm | by Michelle Ma, Univ. of Washington | News | Comments

There is no cure for Alzheimer’s disease and other forms of dementia, but the research community is one step closer to finding treatment. Univ. of Washington bioengineers have a designed a peptide structure that can stop the harmful changes of the body’s normal proteins into a state that’s linked to widespread diseases such as Alzheimer’s, Parkinson’s, heart disease, Type 2 diabetes and Lou Gehrig’s disease.

Technology translation engine launches “organs-on-chips” company

July 28, 2014 10:07 am | News | Comments

The Wyss Institute for Biologically Inspired Engineering at Harvard Univ. announced that its human “Organs-on-Chips” technology will be commercialized by a newly formed private company to accelerate development of pharmaceutical, chemical, cosmetic and personalized medicine products.

Virus drugmaker fights pediatricians' new advice

July 28, 2014 12:17 am | by Lindsey Tanner - AP Medical Writer - Associated Press | News | Comments

A costly drug given mostly to premature babies is at the center of a clash between the manufacturer and the nation's leading pediatrician's group, which recommends scaling back use of the medicine. The dispute involves new guidelines from the American Academy of Pediatrics, which say medical evidence shows the drug benefits few children other than very young preemies.

Novel virus discovered in half the world’s population

July 25, 2014 7:14 am | by Michael Price, San Diego State Univ. | Videos | Comments

Virologists and biologists in California have identified a highly abundant, never-before-described virus that could play a major role in obesity, diabetes. The virus, named crAssphage, has about 10 times as many base pairs of DNA as HIV and infects one of the most common types of gut bacteria. This phylum of bacteria is thought to be connected with obesity, diabetes and other gut-related diseases.

Diseases of another kind

July 24, 2014 8:10 am | by Julie Cohen, Univ. of California, Santa Barbara | News | Comments

The drought that has the entire country in its grip is affecting more than the color of people’s lawns. It may also be responsible for the proliferation of a heat-loving amoeba commonly found in warm freshwater bodies, such as lakes, rivers and hot springs, which the drought has made warmer than usual this year.

Study links enzyme to autistic behaviors

July 23, 2014 4:16 pm | by Iqbal Pittalwala, Univ. of California, Riverside | News | Comments

Fragile X syndrome (FXS) is a genetic disorder that causes obsessive compulsive and repetitive behaviors, and other behaviors on the autistic spectrum, as well as cognitive deficits. It’s the most common inherited cause of mental impairment and the most common cause of autism. Now biomedical scientists at the Univ. of California, Riverside have published a study that sheds light on the cause of autistic behaviors in FXS.

FDA approves Gilead Sciences drug for three cancers

July 23, 2014 1:22 pm | by The Associated Press | News | Comments

The U.S. Food and Drug Administration on Wednesday approved a new cancer drug from Gilead Sciences Inc. to treat three types of blood cancer. Regulators approved the drug for patients with forms of chronic lymphocytic leukemia, follicular lymphoma and small lymphocytic lymphoma. The cancers affect an estimated 200,000 patients in the U.S., according to Gilead.

Researchers create vaccine for dust-mite allergies

July 23, 2014 8:32 am | by Richard C. Lewis, Univ. of Iowa | News | Comments

If you’re allergic to dust mites, help may be on the way. Researchers at the Univ. of Iowa have developed a vaccine that can combat dust-mite allergies by naturally switching the body’s immune response. In animal tests, the nano-sized vaccine package lowered lung inflammation by 83% despite repeated exposure to the allergens.

HIV pills show more promise to prevent infection

July 22, 2014 3:23 am | by The Associated Press | News | Comments

There is more good news about HIV treatment pills used to prevent infection in people at high risk of getting the AIDS virus: Follow-up from a landmark study that proved the drug works now shows that it does not encourage risky sex and is effective even if people skip some doses.

All HIV not created equal: Scientists can identify which viruses cause infection

July 21, 2014 8:07 am | by Laura Bailey, Univ. of Michigan | News | Comments

HIV-infected people carry many different HIV viruses and all have distinct personalities—some much more vengeful and infectious than others. Yet, despite the breadth of infectivity, roughly 76% of HIV infections arise from a single virus. Now, scientists believe they can identify the culprit with very specific measurements of the quantities of a key protein in the HIV virus.

HIV diagnosis rate fell by third in U.S. over decade

July 19, 2014 11:17 am | by Mike Stobbe - AP Medical Writer - Associated Press | News | Comments

The rate of HIV infections diagnosed in the U.S. each year fell by one-third over the past decade, a government study finds. Experts celebrated it as hopeful news that the AIDS epidemic may be slowing in the U.S. The reasons for the drop aren't clear. It might mean fewer new infections are occurring. Or that most infected people already have been diagnosed so more testing won't necessarily find many more cases.

Medical marijuana researcher fired by university

July 18, 2014 9:21 pm | by Astrid Galvan - Associated Press - Associated Press | News | Comments

Veterans, medical marijuana activists and scientists welcomed the first federally approved research into pot as a treatment for post-traumatic stress disorder. But their hopes for the research were dashed when the Univ. of Arizona fired researcher Suzanne Sisley, who undertook the study after clearing four years of bureaucratic hurdles.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading